603 related articles for article (PubMed ID: 12595892)
21. In vivo transgene expression using an adenoviral tetracycline-regulated system with neuron-specific enolase promoter.
Bhattacharjee AK; Ueyama T; Kondoh T; Hayashi S; Abouelfetouh A; Sakai N; Saito N; Kohmura E
Biochem Biophys Res Commun; 2004 May; 317(4):1144-8. PubMed ID: 15094388
[TBL] [Abstract][Full Text] [Related]
22. Promoters and serotypes: targeting of adeno-associated virus vectors for gene transfer in the rat central nervous system in vitro and in vivo.
Shevtsova Z; Malik JM; Michel U; Bähr M; Kügler S
Exp Physiol; 2005 Jan; 90(1):53-9. PubMed ID: 15542619
[TBL] [Abstract][Full Text] [Related]
23. Persistent hepatic expression of human apo A-I after transfer with a helper-virus independent adenoviral vector.
Van Linthout S; Lusky M; Collen D; De Geest B
Gene Ther; 2002 Nov; 9(22):1520-8. PubMed ID: 12407424
[TBL] [Abstract][Full Text] [Related]
24. Long-term transgene expression can be mediated in the brain by adenoviral vectors when powerful neuron-specific promoters are used.
Glover CP; Bienemann AS; Hopton M; Harding TC; Kew JN; Uney JB
J Gene Med; 2003 Jul; 5(7):554-9. PubMed ID: 12825194
[TBL] [Abstract][Full Text] [Related]
25. Delivery of GDNF by an E1,E3/E4 deleted adenoviral vector and driven by a GFAP promoter prevents dopaminergic neuron degeneration in a rat model of Parkinson's disease.
Do Thi NA; Saillour P; Ferrero L; Dedieu JF; Mallet J; Paunio T
Gene Ther; 2004 May; 11(9):746-56. PubMed ID: 14724667
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of Tet-on system to avoid transgene down-regulation in ex vivo gene transfer to the CNS.
Johansen J; Rosenblad C; Andsberg K; Møller A; Lundberg C; Björlund A; Johansen TE
Gene Ther; 2002 Oct; 9(19):1291-301. PubMed ID: 12224012
[TBL] [Abstract][Full Text] [Related]
27. Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression.
Perlman H; Liu H; Georganas C; Woods JM; Amin MA; Koch AE; Wickham T; Kovesdi I; Mano T; Walsh K; Pope RM
J Rheumatol; 2002 Aug; 29(8):1593-600. PubMed ID: 12180715
[TBL] [Abstract][Full Text] [Related]
28. GAL4-NF-kappaB fusion protein augments transgene expression from neuronal promoters in the rat brain.
Liu BH; Yang Y; Paton JF; Li F; Boulaire J; Kasparov S; Wang S
Mol Ther; 2006 Dec; 14(6):872-82. PubMed ID: 16904943
[TBL] [Abstract][Full Text] [Related]
29. pUNISHER: a high-level expression cassette for use with recombinant viral vectors for rapid and long term in vivo neuronal expression in the CNS.
Montesinos MS; Chen Z; Young SM
J Neurophysiol; 2011 Dec; 106(6):3230-44. PubMed ID: 21957229
[TBL] [Abstract][Full Text] [Related]
30. Long-term retinal transgene expression with FIV versus adenoviral vectors.
Loewen N; Leske DA; Cameron JD; Chen Y; Whitwam T; Simari RD; Teo WL; Fautsch MP; Poeschla EM; Holmes JM
Mol Vis; 2004 Apr; 10():272-80. PubMed ID: 15094709
[TBL] [Abstract][Full Text] [Related]
31. Gene therapy progress and prospects: adenoviral vectors.
St George JA
Gene Ther; 2003 Jul; 10(14):1135-41. PubMed ID: 12833122
[TBL] [Abstract][Full Text] [Related]
32. Promoters influence the kinetics of transgene expression following adenovector gene delivery.
Chen P; Tian J; Kovesdi I; Bruder JT
J Gene Med; 2008 Feb; 10(2):123-31. PubMed ID: 18064718
[TBL] [Abstract][Full Text] [Related]
33. Neuron-restrictive silencer elements mediate neuron specificity of adenoviral gene expression.
Millecamps S; Kiefer H; Navarro V; Geoffroy MC; Robert JJ; Finiels F; Mallet J; Barkats M
Nat Biotechnol; 1999 Sep; 17(9):865-9. PubMed ID: 10471926
[TBL] [Abstract][Full Text] [Related]
34. Comparison of high-capacity and first-generation adenoviral vector gene delivery to murine muscle in utero.
Bilbao R; Reay DP; Wu E; Zheng H; Biermann V; Kochanek S; Clemens PR
Gene Ther; 2005 Jan; 12(1):39-47. PubMed ID: 15483668
[TBL] [Abstract][Full Text] [Related]
35. A comparative analysis of constitutive and cell-specific promoters in the adult mouse hippocampus using lentivirus vector-mediated gene transfer.
Kuroda H; Kutner RH; Bazan NG; Reiser J
J Gene Med; 2008 Nov; 10(11):1163-75. PubMed ID: 18773500
[TBL] [Abstract][Full Text] [Related]
36. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo.
Gerdes CA; Castro MG; Löwenstein PR
Mol Ther; 2000 Oct; 2(4):330-8. PubMed ID: 11020348
[TBL] [Abstract][Full Text] [Related]
37. Increased glia-specific transgene expression with glial fibrillary acidic protein promoters containing multiple enhancer elements.
de Leeuw B; Su M; ter Horst M; Iwata S; Rodijk M; Hoeben RC; Messing A; Smitt PS; Brenner M
J Neurosci Res; 2006 Apr; 83(5):744-53. PubMed ID: 16496373
[TBL] [Abstract][Full Text] [Related]
38. Insulated hsp70B' promoter: stringent heat-inducible activity in replication-deficient, but not replication-competent adenoviruses.
Rohmer S; Mainka A; Knippertz I; Hesse A; Nettelbeck DM
J Gene Med; 2008 Apr; 10(4):340-54. PubMed ID: 18265421
[TBL] [Abstract][Full Text] [Related]
39. Human blue-opsin promoter preferentially targets reporter gene expression to rat s-cone photoreceptors.
Glushakova LG; Timmers AM; Pang J; Teusner JT; Hauswirth WW
Invest Ophthalmol Vis Sci; 2006 Aug; 47(8):3505-13. PubMed ID: 16877422
[TBL] [Abstract][Full Text] [Related]
40. Transcriptional targeting of adenoviral vector through the CXCR4 tumor-specific promoter.
Zhu ZB; Makhija SK; Lu B; Wang M; Kaliberova L; Liu B; Rivera AA; Nettelbeck DM; Mahasreshti PJ; Leath CA; Yamamoto M; Alvarez RD; Curiel DT
Gene Ther; 2004 Apr; 11(7):645-8. PubMed ID: 15029227
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
